Zacks.com on MSN1h
Sanofi's Sarclisa Gets FDA Nod for Expanded Use in Multiple Myeloma
Sanofi SNY announced that the FDA has approved the label expansion for the use of its multiple myeloma (MM) drug, Sarclisa ...
Sanofi's Sarclisa Secures FDA Approval For First-Line Multiple Myeloma, Marking Its Third US Approval
Sarclisa (siltuximab) in combination with bortezomib, lenalidomide, and dexamethasone (VRd) as a first-line treatment option ...
Ventyx Biosciences Announces $27 Million Strategic Investment from Sanofi
Sanofi to receive an exclusive right of first negotiation for Ventyx’s CNS-penetrant NLRP3 inhibitor VTX3232SAN DIEGO, Sept. 23, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: VTYX) (“Ventyx”), a clinical-stage ...
Multiple Sclerosis News Today10h
ECTRIMS 2024: Tolebrutinib may target smoldering inflammation
The totality of data from Sanofi clinical trials indicates that Tolebrutinib may target inflammation thought to contribute to ...